Skip to content

Sauna Bathing to Improve Vascular Health of Adults With Heart Disease

Effects of Sauna Bathing on Cerebrovascular Function in Middle-aged to Older Adults With Heart Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03620539
Enrollment
61
Registered
2018-08-08
Start date
2018-12-04
Completion date
2022-09-12
Last updated
2023-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

flow-mediated dilation, sauna, vascular, heat

Brief summary

This study is a clinical trial that will determine if sauna bathing improves blood vessel health in adults aged 50-70 years with heart disease.

Detailed description

Mounting evidence suggests that heat therapy may improve cardiovascular health. Recent analyses of a large cohort of middle-aged to older Finnish men have established that frequent sauna bathing is associated with a reduced risk of cardiovascular mortality, of developing dementia and Alzheimer's disease, and of developing hypertension. Given the observational nature of these relationships, it remains unknown if the beneficial effects of sauna bathing can be directly attributed to heat exposure. The objective of this study is to test the primary hypothesis that 8 weeks of sauna bathing improves flow-mediated dilation, a measure of blood vessel health, in middle-aged to older adults (50-70 yrs) with stable coronary artery disease.

Interventions

OTHERLifestyle intervention

Sauna bathing

Sponsors

Montreal Heart Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. A history of angiographic coronary disease: ≥70% arterial diameter narrowing of at least one major epicardial coronary artery and/or prior coronary revascularization and/or documented prior acute coronary syndrome and/or perfusion defect during exercise testing or pharmacological stimulation 2. Stable medication doses (≥4 weeks) prior to enrolment 3. Body mass index \<35 kg/m2

Exclusion criteria

1. Recent (\<3 months) coronary artery disease-related hospitalization or change in angina pattern 2. Unstable angina 3. Ejection fraction \<40% and/or clinical evidence of heart failure 4. Significant valvular heart disease 5. Uncontrolled hypertension (\>180/110 mmHg)

Design outcomes

Primary

MeasureTime frameDescription
Flow-mediated dilationChange from baseline after 8 weeksBrachial artery flow-mediated dilation in response to 5 minutes of forearm occlusion

Secondary

MeasureTime frameDescription
Post-occlusion reactive hyperaemia (AUC)Change from baseline after 8 weeksVascular conductance area-under-the-curve during reactive hyperaemia induced by 5 minutes of forearm occlusion
Post-occlusion reactive hyperaemia (Peak)Change from baseline after 8 weeksPeak vascular conductance during reactive hyperaemia induced by 5 minutes of forearm occlusion
Local skin heating-induced vasodilationChange from baseline after 8 weeksPlateau of the cutaneous vascular conductance response during local heating of the skin to 39°C

Other

MeasureTime frameDescription
Heart rate variabilityChange from baseline after 8 weeksResting levels of heart rate variability
Blood pressureChange from baseline after 8 weeksSystolic blood pressure at rest
Central arterial stiffnessChange from baseline after 8 weeksCarotid-femoral pulse wave velocity

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026